Classified in: Science and technology
Subject: Product/Service
The future of genetics must be open.
Nucleus Genomics today launched Nucleus Labs, its new AI genomics research arm, and released Origin, a family of nine genetic optimization models that outperform all previous accuracy benchmarks in predicting health and longevity from an embryo’s DNA.
Trained and validated on millions of people, Origin forecasts risks for age-related conditions like heart disease and cancer across diverse ancestries. With just five embryos, couples can expect a greater than 50% risk reduction in common diseases like Alzheimer’s, diabetes, and cancers.
For couples pursuing IVF, Origin offers a new way to plan for long-term health from the very start of life. Families and clinicians can now make more informed decisions about their future child’s wellbeing. It represents a fundamental change in how IVF is conducted and sets a new standard of scientific rigor in reproductive genetics.
Why it matters
In a first for the genomics industry, Nucleus is making its science completely transparent by open-weighting its models. In doing so, patients, researchers, clinicians, and companies can now access and build upon the research.
“Too much of genetic optimization has been shrouded in secrecy,” said Kian Sadeghi, Founder and CEO of Nucleus Genomics. “We reject that. There’s enormous potential to improve lifelong health starting before birth ? and IVF is where that potential becomes real. Progress in genomics will now be faster and safer because of the launch of Origin.”
Driving transparency: A new standard in reproductive genetics
Alongside the launch, Nucleus introduced the Genetic Optimization Hub ? a place for industry leaders and top researchers to show their work and improve genetic prediction. Nucleus has open-weighted its Origin family of models on the hub, and has invited other researchers and companies to do the same.
Nucleus wants to encourage open collaboration across IVF and medical research to ensure responsible and rapid innovation.
A turning point for genomics
The release of Origin is the first in a planned series of open-weight models. Nucleus says future models will expand optimization power even further, while setting new norms for transparency, safeguards, and responsible use.
“Technology doesn’t exist in a vacuum,” added Sadeghi. “Its impact depends on how responsibly it’s used. By open-weighting Origin, we want to set a global standard for safe, equitable, and effective genetic optimization.”
About Nucleus Genomics
Nucleus Genomics builds clinical-grade genetics software focused on generational health. Its flagship product, Nucleus IVF+, integrates deep genomic insight into IVF ? enabling families to plan for health and longevity from the earliest stage. Learn more.
To partner with Nucleus, please reach out to [email protected].
Videotron Ltd. (“Videotron”) today announced that it has issued a conditional notice of redemption for all of its outstanding 51/8% Senior Notes due April 15, 2027 (the “Notes”), of which there is US$600 million aggregate principal amount outstanding…
Bone Solutions Inc., a Colleyville-based orthobiologics company specializing in magnesium-based technologies, announced that the U.S. Food and Drug Administration (FDA) has granted pediatric clearance for its Mg OSTEOCRETE and Mg OSTEOINJECT…
Digital Turbine, Inc. , a global mobile platform company, announced it will host a conference call and webcast to discuss its fiscal 2026 second quarter financial results and operating progress on Tuesday, November 4th, at 4:30pm ET/1:30pm PT. The…
DelveInsight’s Emphysema Market Insights report includes a comprehensive understanding of current treatment practices, emphysema emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented…
BIOQUAL, Inc. www.bioqual.com BIOQ(Pink Limited):
Three Months Ended
August 31,
2025
2024
Revenue
$
9,855,399
$
11,770,482
Loss…
Videotron Ltd. (“Videotron”) today announced the pricing of its C$800 million aggregate principal amount of 3.950% Series 3 Senior Notes due October 15, 2032 (the “Notes”) (this offering, the “Offering”). The Notes will be sold at C$999.37 per…
News published on 21 october 2025 at 10:05 and distributed by:
